GlassScriptPhysician profile
Joel M Burroughs
NPI 1710951785
$1,654.65
in general payments reported to CMS, 2019-2025
26 companies · $1,001 in 2025
The $1,001 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.88 · 2021: $56.60 · 2022: $66.81 · 2024: $519 · 2025: $1,001.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,519.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $251.98 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $181.01 | 2024-2025 | |
| Lilly USA, LLC | $146.32 | 2024-2025 | Mounjaro, Zepbound |
| Amgen INC. | $144.25 | 2024-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $120.55 | 2024-2025 | Airsupra, Farxiga, Flumist Quadrivalent |
| Abbvie INC. | $111.37 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.53 | 2024-2025 | Xifaxan |
| Exact Sciences Corporation | $72.86 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $68.73 | 2021-2025 | Trintellix |
| Corcept Therapeutics | $54.76 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $53.79 | 2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.43 | 2024-2025 | Jardiance |
| Esperion Therapeutics, INC. | $51.01 | 2024-2025 | Nexletol |
| Ani Pharmaceuticals, INC. | $29.79 | 2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $25.93 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $22.97 | 2025 | Rexulti |
| Dexcom, INC. | $21.88 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $21.43 | 2025 | |
| Recordati_rare_diseases_inc. | $20.09 | 2025 | Isturisa |
| Merck Sharp & Dohme LLC | $18.22 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Inspire Medical Systems, INC. | $17.45 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.22 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $15.22 | 2024 | Gvoke Hypopen |
| Noven Therapeutics, LLC | $14.94 | 2024 | Xelstrym, Secuado |
| Otsuka America Pharmaceutical, INC. | $14.88 | 2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $14.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Burroughs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.